Home

The reproductive and drug safety advisory panels just voted on the safety of Bayer's drospirenone oral contraceptives. The verdict: 15-11 voted that the pill's risks outweighed any possible benefits and 21-5 voted that the pill's information label needs to be amended to include a possible increased risk of blood clots.

According to one study published by the FDA in October, women using drospirenone contraceptives (such as Yaz or Yasmin) were 74% more likely to suffer blood clots than women using another type of hormonal contraceptive.

Although studies of Yaz and Yasmin have been inconclusive, the FDA does feel the need to warn consumers of the possible dangers associated with drospirenone. The FDA has taken a similar stance on Johnson & Johnson's Ortho Evra birth control patch, which has also been associated with an increased risk of clotting.

 
Have You Been Injured?
Free Claim Review
If you or a loved one have suffered a serious injury or side effect related to drug or supplement, please contact us for a free and confidential case review.
 

 

 

 

 

 

 

 

 



 

 

 

 

 

  
 
 
Polls
Do You Think The FDA Is Doing Enough To Protect Consumers?
 
Facebook MySpace Twitter Digg Delicious Stumbleupon Google Bookmarks RSS Feed